設計及合成含藥物之新穎鉑錯合物

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：31

、訪客IP：3.15.14.245

姓名

葉子聖(Tzu-sheng Yeh) 查詢紙本館藏

畢業系所

化學學系

論文名稱

設計及合成含藥物之新穎鉑錯合物
(Design and Synthesis of New Drug-Containing PlatinumComplexes)

相關論文

★ 合成醯胺鍵及胺鍵連結之鳥苷與香豆素共軛化合物並探討其構形	★ 合成含腺嘌呤核苷之新型奈米碳管
★ 合成具有抗病毒潛力的香豆素與腺嘌呤、腺苷、肌苷之胺鍵標靶共軛化合物	★ 合成腺苷與含氮雜環之硫烷鍵共軛化合物作為抗病毒試劑
★ 腺苷與香豆素共軛連結化合物之合成與其構形之探討	★ 探討電子效應和立體障礙對於「胺基醇」轉換成烯類化合物之影響
★ 探討β胺醇之α碳上立體障礙與電子效應對苯炔誘導形成碳與碳雙鍵反應之影響	★ 研究「二苯並環庚烯」及「脂芳烴」之「阿昔洛韋」共軛化合物的結構與抗病毒活性的關係
★ 合成具有抗腸病毒活性「二苯」及「亞甲基二苯」與「阿昔洛韋」之共軛化合物	★ 合成脲鍵連結之「去甲替林」與「核苷」共軛化合物用作抗腸病毒藥劑
★ 合成「核苷」與「金剛胺」連結之脲鍵化合物作為抗病毒藥劑	★ 合成含胺基酸酯之「無環鳥苷」與「去甲替林」共軛化合物作為抗腸病毒藥劑
★ 探討合成含四級胺鹽之金奈米粒子之條件	★ 苯并咪唑與香豆素共軛連結化合物之合成與其構型之探討
★ 合成醯胺鍵結苯并咪唑與香豆素之化合物並探討其構形

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

於本篇論文中，本人發展一系列具有雙重功效的抗癌前驅藥物之新型有機鉑錯合物的合成路徑。此外，本人亦藉由核磁共振光譜儀(NMR)、傅立葉轉換紅外線光譜儀(FTIR)、紫外光光譜儀(UV)之技術來討論Vorinostat (5)、Acetohydroxamic acid (7)、Bufexamac (9) and Hydroxyurea (12)這些抗癌藥物與鉑金屬之間的鍵結，首先Vorinostat (5)經由實驗及光譜證明是以Hydroxamic acid官能基中的N原子與Sulfoplatin (4)之鉑金屬鍵結，Acetohydroxamic acid (7)、Bufexamac (9)這兩個一樣含有Hydroxamic acid官能基的藥物於更進一步的實驗也被證明是以Hydroxamic acid官能基中的N原子與Sulfoplatin (4)之鉑金屬鍵結，Hydroxyurea (12)和前述Vorinostat (5)、Acetohydroxamic acid (7) and Bufexamac (9)三種藥物一樣具有Hydroxamic acid官能基，但是此藥物卻無法和Sulfoplatin (4)反應，而無法得到我們所預期的產物。最後我們合成出新穎鉑錯合物6, 8, 10且發展出以Hydroxamic acid官能基與鉑金屬鍵結的方法，也確定了其鍵結的形式，此類含Hydroxamic acid官能基的藥物預期於將來會有更多更深入的研究與發展。

摘要(英)

A synthetic pathway of novel organoplatinum complex as anti-cancer prodrugs with dual functions was developed. On the other hand, we investigated the binding mod of drugs “Vorinostat (5)、Acetohydroxamic acid (7)、Bufexamac (9) and Hydroxyurea (12)” to platinum metal by NMR(Nuclear magnetic resonance), FTIR(Fourier transform infrared), UV (Ultraviolet) spectroscopy. First the binding mod between Vorinostat (5) and Sulfoplatin (4) was proved by experiments and spectroscopy, Vorinostat (5) binding to Sulfoplatin (4) with nitrogen atom in hydroxamic acid functional group. Acetohydroxamic acid (7) and Bufexamac (9) with hydroxamic acid functional group also show the same binding mod with Sulfoplatin (4) just like Vorinostat (5). Hydroxyurea (12) and the aforementioned drugs “Vorinostat (5), Acetohydroxamic acid (7) and Bufexamac (9)” has the same hydroxamic acid functional group, but it did not work in the same experimental conditions as aforementioned drugs “Vorinostat (5), Acetohydroxamic acid (7) and Bufexamac (9)”, it will be discussed in this contents of my thesis. Furthermore, the platinum complex 6, 8, 10 with hydroxamic acid functional group was expected for more study and investigation in the future.

關鍵字(中)

★ 鉑
★ 藥物

關鍵字(英)

★ drug
★ platinum

論文目次

中文摘要 ..............................................................................................................i
英文摘要 .............................................................................................................ii
謝誌 ....................................................................................................................iii
目錄 ....................................................................................................................iv
圖目錄 ................................................................................................................vi
一、緒論 .........................................................................................................1
二、結果 .........................................................................................................7
2-1 合成具有雙重功效之新穎鉑錯合物 (6)、(8)、(10) ..............................7
2-2 Vorinostat (5)和Sulfoplatin (4)間之鍵結測試 ......................................9
2-3 反應條件測試 .....................................................................................10
三、討論 .......................................................................................................12
3-1 Vorinostat (5)和Sulfoplatin (4)之間鍵結之探討 ................................12
3-2 Hydroxyurea (12)和Sulfoplatin (4)反應之探討 .................................12
3-3 進一步探討Hydroxamic acid官能基和Sulfoplatin (4)之鍵結 ........13
3-4高效能液相層析儀之純度探討............................................................18
四、結論 .......................................................................................................22
五、實驗部份 ...........................................................................................23
(Dimethylsulfoxide-S)(N1-hydroxy-N8-phenyloctane-1,8-diamido-N1)(η2-2-mercaptopyridine N-oxido-O,S)platinum(II) (6)之合成 ..........................24
(Dimethylsulfoxide-S)(N-hydroxyacetamido-N)(η2-2-mercaptopyridine N-oxido-O,S)platinum(II) (8)之合成 ........................................................25
(Dimethylsulfoxide-S)(4-butoxy-N-hydroxybenzeneacetamido-N)(η2-2-mercaptopyridine N-oxido-O,S)platinum(II) (10)之合成 ...............................26
六、參考文獻 ...........................................................................................28
七、光譜 .......................................................................................................31

參考文獻

1. Barnard, C. F. J. Plat. Met. Rev. 1989, 33, 162–167.
2. Stewart, D. J. Crit. Rev. Oncol. Hematol. 2007, 63, 12–31.
3. For reviews, see: (a) Reedijk, J. J. Chem. Soc., Chem. Commun. 1996, 801–806; (b) Fuertes, M. A.; Alonso, C.; Perez, J. M. Chem. Rev. 2003, 103, 645–662; (c) Chupin, V.; de Kroon, A. I. P. M.; de Kruijff, B. J. Am. Chem. Soc. 2004, 126, 13816–13821; (d) Mandal, R.; Kalke, R.; Li, X. F. Chem. Res. Toxicol. 2004, 17, 1391–1937; (e) Tacka, K. A.; Dabrowiak, J. C.; Goodisman, J.; Penefsky, H. S.; Souid, A. K. Chem. Res. Toxicol. 2004, 17, 1102–1111; (f) Tacka, K. A.; Szalda, D.; Souid, A. K.; Goodisman, J.; Dabrowiak, J. C. Chem. Res. Toxicol. 2004, 17, 1434–1444; (g) Ruiz, J.; Lerenzo, J.; Sanglas, L.; Cutillas, N.; Vicente, C.; Villa, M. D.; Avilés, F. X.; López, G.; Moreno, V.; Pérez, J.; Bautista, D. Inorg. Chem. 2006, 45, 6347–6360; (h) Liu, X.; Shen, H.; Zhu, H. B.; Cui, K.; Gou, S. H. Bioorg. Med. Chem. Lett. 2007, 17, 3831–3834; (i) Yu, Y.; Lou, L. G.; Liu, W. P.; Zhu, H. J.; Ye, Q. S.; Chen, X. Z.; Gao, W. G.; Hou, S. Q. Eur. J. Med. Chem. 2008, 43, 1438–1443; (j) Coley, H. M.; Sarju, J.; Wagner, G. J. Med. Chem. 2008, 51, 135–141.
4. Sigman, D. S.; Bruice, T. W.; Mazumder, A.; Sutton, C. L. Acc. Chem. Res. 1993, 26, 98–104.
5. For reviews, see: (a) Stubbe, J.; Kozarich, J. W. Chem. Rev. 1987, 87, 1107–1136; (b) Pogozelski, W. K.; Tullius, T. D. Chem. Rev. 1998, 98, 1089–1108; (c) Burrows, C. J.; Muller, J. G. Chem. Rev. 1998, 98, 1109–1151; (d) Cowan, J. A. Curr. Opin. Chem. Biol. 2001, 5, 634–642.
6. Bowler, B. E.; Hollis, L. S.; Lippard, S. J. J. Am. Chem. Soc. 1984, 106, 6102–6104.
7. Grokhovsky, S. L.; Zubarev, V. E. Nucl. Acids Res. 1991, 19, 257–264.
8. Yavin, E.; Stemp, E. D. A.; Weiner, L.; Sagi, I.; Yellin, R. A.; Shanzer, A. J. Inorg. Biochem. 2004, 98, 1750–1756.
9. Lampers, E. L. M.; Bashkin, J. S.; Kostic, N. M. Nucl. Acids Res. 1993, 21, 1983–1990.
10. Breiner, K. M.; Daugherty, M. A.; Oas, T. G.; Thorp, H. H. J. Am. Chem. Soc. 1995, 117, 11673–11679.
11. Brown, S. D.; Nativo, P.; Smith J.-A.; Stirling, D.; Edwards, P. R.; Venugopal, B.; Flint, D. J.; Plumb, J. A.; Graham, D.; Wheate, N. J. J. Am. Chem. Soc. 2010, 132, 4678–4684.
12. Aryal, S.; Hu, C.-M. J.; Zhang, L. ACS Nano, 2010, 4 (1), 251–258
13. Dhar, S.; Liu, Z.; Thomale, J.; Dai, H.; Lippard, S. J. J. Am. Chem. Soc. 2008, 130, 11467–11476.
14. Klein, A. V.; Hambley T. W. Chem. Rev. 2009, 109, 4911–4920.
15. Bruhn, S. L.; Toney, J. H.; Lippard, S. J. Progress in Inorganic Chemistry : Bioinorganic Chemistry, 1990, 38, 477–516.
16. Lu, K. L.; Hwu, J. R.; Tsay, S. C.; Yu, S. F.; Hung, J. T.; Huang, J. J. U. S. Patent US 6458 833 B1 2002.
17. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Nat. Rev. Drug. Discov. 2008, 7, 255–270.
18. John, C. S.; Rachel, I. H.; Lainie, V. V. J. Med. Chem. 1995, 38, 1411–1413.
19. http://www.fda.gov/
20. Henderson, W.; Evans, C.; Nicholson, B. K.; Fawcett, J. Dalton Trans., 2003, 2691–2697.

指導教授

胡紀如(Jih Ru Hwu)

審核日期

2010-7-16

推文